Anhydrous Selenium Disulfide Compositions Without Particle Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing selenium disulfide formulations for treating meibomian gland dysfunction suffer from aggregation, chemical instability, and require surfactants and dispersing agents, leading to undesirable ocular surface interactions and reduced efficacy.
Innovation Solution
Anhydrous selenium disulfide compositions are developed, free of surfactants and dispersing agents, with stable, non-aggregated particles dispersed in an anhydrous semi-solid ophthalmic base, maintaining chemical stability and preventing ocular surface contact.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If selenium disulfide is formulated with surfactants and dispersing agents, then it can be dispersed in the formulation, but it causes undesirable ocular surface interactions and reduced efficacy
Solution Approach 1:
The patent removes surfactants and dispersing agents from the formulation entirely, extracting the harmful components while maintaining dispersion stability through alternative means (anhydrous base and controlled particle size)
Solution Approach 2:
The patent changes the formulation parameters by using an anhydrous base instead of aqueous systems, and controls particle size within specific ranges (0.1-10 μm), which fundamentally alters how selenium disulfide disperses and interacts with the ocular surface
2Device complexity
If selenium disulfide particles are not properly dispersed, then the formulation is simpler, but it causes aggregation and chemical instability
Solution Approach 1:
The patent specifies precise particle size parameters (0.1-10 μm) and uses an anhydrous base, transforming the physical and chemical state of the formulation to prevent aggregation while maintaining simplicity
3Reliability
If selenium disulfide formulations are applied to the ocular surface, then they can treat meibomian gland dysfunction, but they cause diffusion onto the ocular surface and aggregation
Solution Approach 1:
The patent applies the formulation locally to the eyelid margin rather than the ocular surface itself, and uses specific particle size ranges to ensure the selenium disulfide remains at the target site without diffusing or aggregating
Solution Approach 2:
By controlling particle size (0.1-10 μm) and using an anhydrous base, the patent changes the physical parameters that govern diffusion and aggregation behavior, preventing harmful effects while maintaining treatment efficacy
Data Source
AI summary
Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said methods are performed by administering said composition comprising a selenium disulfide and an anhydrous semi-solid base. The stable anhydrous composition are substantially free of selenium disulfide agglomerates.